We first compared the clinical characteristics of

2.5. Funding
The study was funded by the National Institutes of Health, National Institute of General Medical Sciences. The funder played no other role in the study, in the writing of the manuscript, or in the decision to submit the manuscript.
3. Results
3.1. Prospective Validation of tPERSEVERE
Table 1 shows the demographic and clinical characteristics of the validation cohort (n = 168). Sixty-three subjects (38%) had a complicated course. Among these, 25 (40%) died by study day 28. Compared to subjects with a non-complicated course, those Diosmetin in the complicated course group had a higher PRISM score, a higher PERSEVERE mortality probability, and a greater proportion had immune suppression or had undergone previous bone marrow transplantation. No other differences were noted.
Table 1.
    Demographic and clinical characteristics of the validation cohort.Non-complicated courseComplicated courseN (%)105 (63)63 (38)Median age, years (IQR)5.3 (1.8–12.8)4.8 (1.1–14.9)Males, # (%)60 (57)37 (59)28-day mortality, # (%)0 (0)25 (40)Median PRISM score (IQR)10 (7–15)13 (8–21)1PERSEVERE mortality probability (95% C.I.)6.5 (4.6–8.4)12.9 (9.5–16.3)2# With gram negative bacteria (%)27 (26)15 (24)# With gram positive bacteria (%)19 (18)14 (22)# With other pathogen isolated (%)9 (9)5 (8)# With no pathogen identified (%)50 (48)29 (46)# With comorbidity (%)67 (64)47 (75)# With malignancy (%)20 (19)16 (25)# With immune suppression (%)20 (19)22 (35)3# With bone marrow transplantation (%)4 (4)10 (16)31p < 0.05 vs. respiration non-complicated course; Rank sum test.2p < 0.05 vs. non-complicated course; t-test.3p < 0.05 vs. non-complicated course; Chi-square.Full-size tableTable optionsView in workspaceDownload as CSV